Lv4
478 积分 2025-11-10 加入
Exploring LRRK2-dependent Mechanisms in Parkinson’s Disease Therapy
17小时前
已关闭
Research progress of PROTACs for neurodegenerative diseases therapy
1天前
已完结
Discovery of the First Clinical Protein Degrader for the Treatment of Autoimmune Indications: Orally Bioavailable and Selective IRAK4 Degrader KT-474
2天前
已完结
BGB-45035, a selective IRAK4 CDAC, demonstrated fast IRAK4 degradation and strong signaling inhibition, and superior efficacy in preclinical disease models 2529
2天前
已完结
IRAK family in inflammatory autoimmune diseases
2天前
已完结
252 Safety, Pharmacokinetics and Pharmacodynamics of KT-621, an Oral STAT6 Degrader, in Healthy Adults
3天前
已关闭
Late Breaking Abstract - Safety, pharmacokinetics and pharmacodynamics of KT-621, an oral STAT6 degrader, in healthy adults
3天前
已关闭
STAT4 and STAT6, their role in cellular and humoral immunity and in diverse human diseases
3天前
已完结
Heat Shock Protein 90 Interactome-Mediated Proteolysis Targeting Chimera (HIM-PROTAC) Degrading Glutathione Peroxidase 4 to Trigger Ferroptosis
5天前
已完结
Design, synthesis, and induction of tumor ferroptosis activity of a novel FSP1 protein degrading agent
5天前
已完结
皖公网安备34019202002308
